Ken Griffin Aura Biosciences, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Aura Biosciences, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 400 shares of AURA stock, worth $2,724. This represents 0.0% of its overall portfolio holdings.
Number of Shares
400
Previous 200
100.0%
Holding current value
$2,724
Previous $1,000
200.0%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding AURA
# of Institutions
79Shares Held
39.9MCall Options Held
400Put Options Held
1.5K-
Matrix Capital Management Company, LP Waltham, MA6.92MShares$47.1 Million0.5% of portfolio
-
Eventide Asset Management, LLC Boston, MA5.8MShares$39.5 Million0.73% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA4.47MShares$30.4 Million0.07% of portfolio
-
Medicxi Ventures Management (Jersey) LTD3.04MShares$20.7 Million6.26% of portfolio
-
Black Rock Inc. New York, NY2.44MShares$16.6 Million0.0% of portfolio
About Aura Biosciences, Inc.
- Ticker AURA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,273,600
- Market Cap $199M
- Description
- Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develop...